Safety: poisonings, drug interactions, legal status, and harm reduction

1. Risk Overview: Systematization by Mushroom Type

#

⚠️ Classification of Mushrooms by Toxicity Mechanism

#

Mushroom poisonings are classified based on the toxins they contain and the clinical syndromes they cause. Understanding these distinctions is critically important for diagnosis and treatment.

Major Toxic Syndromes:

1. Amatoxin Syndrome (Amanita phalloides, Lepiota brunneoincarnata)

   • Latent period: 6-12 hours
   • Mortality: 30-90% without treatment, <10% with early intensive care
   • ☠️ The deadliest syndrome

2. Muscarinic Syndrome (Inocybe, Clitocybe)

   • Latent period: 30 minutes — 2 hours
   • Prognosis: excellent, fatalities extremely rare

3. Ibotenic/Muscimol Syndrome (Amanita muscaria, A. pantherina)

   • Latent period: 30 minutes — 2 hours
   • Mortality: extremely rare

4. Psilocybin Syndrome (Psilocybe, Panaeolus)

   • Latent period: 15-60 minutes
   • Physical toxicity: low
   • Psychological risks: present

Methods of Use and Associated Risks

#

Fresh mushrooms:

• High potency variability
• Risk of misidentification
• Contamination with pathogens/parasites

Dried mushrooms:

• More stable potency
• Long-term storage
• Risk of misidentification remains

Extracts and supplements:

• Unknown purity
• Possible species substitution
• Heavy metal/pesticide contamination
• Lack of dosage standardization

Synthetic derivatives:

• Known chemical structure
• Controlled dosage
• Legal risks (most prohibited)

2. Mushroom Poisonings: Statistics and Clinical Syndromes

#

European Statistics

#

☠️ TOXIC: Mushrooms containing cyclopeptide amatoxin are responsible for more than 90% of mushroom poisoning deaths. Mortality currently stands at less than 10%, representing a significant improvement over historical rates.

Retrospective analysis from Northern Italy (21 years):

• 13 cases of muscarinic toxicity (usually Inocybe or Clitocybe spp.)
• 20 cases of amatoxin poisoning (11 Amanita phalloides and 9 Lepiota brunneoincarnata)

☠️ Amatoxin Syndrome

#

Pathophysiology:

α-amanitin inhibits RNA polymerase II, causing protein deficiency and ultimately cell death. Amatoxins are thermostable: they are resistant to temperature changes, so their toxic effects are not reduced by either cooking or freezing.

Clinical Phases:

1. Phase 1 (6-12 hours): Onset of nausea, abdominal cramps, profuse watery diarrhea, and signs of dehydration
2. Phase 2 (24-48 hours): Patient appears to be recovering, gastrointestinal symptoms resolve, but liver damage continues
3. Phase 3 (72+ hours): Fulminant hepatic failure

Treatment and Outcomes:

Early hospitalization, rapid diagnosis, and aggressive treatment have reduced mortality to 10%, whereas a 60-hour delay increases it to 50-90%.

Effectiveness of Different Approaches:

• Penicillin only: 22% mortality
• Combined therapy penicillin + silibinin: 9%
• Silibinin monotherapy: 5%

Liver transplantation remains the mainstay of treatment in selected patients with fulminant hepatic failure.

Muscarinic Syndrome

#

Pathophysiology:

Muscarine is a natural product found in certain mushrooms, especially Inocybe and Clitocybe species. It causes cholinergic toxicity.

Cholinergic Symptoms:

Abdominal cramps, diaphoresis (sweating), salivation, lacrimation, bronchospasm, bronchorrhea, and bradycardia typically occur within 30 minutes. Within minutes to an hour after ingestion, patients may develop the classic cholinergic syndrome consisting of:

• Diaphoresis (sweating)
• Bradycardia (slow pulse)
• Bronchospasm
• Profuse bronchorrhea (excessive mucus secretion)
• Miosis (pupil constriction)
• Seizures
• Salivation and lacrimation
• Involuntary loss of urine and stool
• Vomiting

Duration and Prognosis:

Duration is dose-dependent, though typically shorter compared to other sources of cholinergic poisoning, such as pesticides. With muscarinic poisoning, the entire episode typically resolves within 6-8 hours; some symptoms may completely resolve up to 24 hours.

The prognosis for muscarinic poisoning is excellent, and fatalities are very rare.

Treatment:

Most patients with mushroom poisoning containing muscarine can be treated without medication. If patients exhibit excessive bronchial secretions or other symptoms of cholinergic excess (bradycardia) that cause significant concern, atropine can reduce these symptoms.

Atropine Dosage:

• Adults: 0.5-1 mg intravenously
• Pediatric patients: 0.01 mg/kg

Intravenous fluids if vomiting becomes pronounced, though this rarely proves necessary.

Ibotenic/Muscimol Syndrome

#

See detailed description in the “Toxicology” section of https://lucerna.folkup.app/studies/mushroom-brain-amanita/.

Brief Characteristics:

• Biphasic effect: GABAergic (muscimol) + glutamatergic (ibotenic acid)
• Symptoms: drowsiness, confusion, hallucinations, delirium, hyperactivity, ataxia, myoclonus
• Onset: 30 minutes — 2 hours
• Duration: 6-24 hours
• Fatalities extremely rare

3. Supplement Contamination: Heavy Metals and Species Substitution

#

The Problem of Lack of Standardization

#

⚠️ WARNING: The FDA does not approve dietary supplements, and these products do not require prior safety review or approval before entering the market.

Supplement quality varies significantly, with potential issues including:

• Incorrect labeling
• Filler ingredients
• Contamination
• Heavy metals
• Inconsistent potency depending on sources and processing methods

Heavy Metals in Mushroom Supplements

#

Mushrooms have the ability to accumulate heavy metals from soil (bioaccumulation). This makes them useful for bioremediation but dangerous for consumption when grown in contaminated areas.

Major Contaminants:

• Lead (Pb)
• Cadmium (Cd)
• Mercury (Hg)
• Arsenic (As)

Example Violations:

One dietary supplement manufacturer did not conduct tests to verify the identity of dietary ingredients and instead randomly conducted heavy metal analysis of these dietary ingredients.

FDA Warnings

#

The FDA has issued several warning letters against companies selling supplements with Lion’s Mane, Antrodia, Maitake, Reishi, and Cordyceps mushrooms. However, these warnings primarily focused on illegal disease treatment claims, not specifically on heavy metal contamination.

Typical Violations:

• Therapeutic claims without FDA approval
• Marketing as drugs without license
• Lack of proper quality control

Species Substitution

#

A serious problem in the mushroom supplement industry is the substitution of more expensive species with cheaper ones. Microscopic and genetic analysis is often absent.

Examples:

• Mycelium on grain substrate instead of fruiting bodies
• Substitution of Ganoderma lucidum (reishi) with cheaper species
• Synthetic muscimol instead of Amanita muscaria extract

Pesticides and Contaminants

#

Cultivated mushrooms may contain residues of pesticides, fungicides, and other agrochemicals used in cultivation.

4. Drug Interactions

#

⚠️ SSRI/SNRI and Serotonin Syndrome

#

Classic Psychedelics (psilocybin, LSD, DMT) + SSRI/SNRI:

Recent studies evaluating the safety of concurrent use of antidepressants and classic psychedelics found no signs of serotonergic toxicity or syndrome in ten studies.

However, there is a trade-off: chronic SSRI use has been shown to reduce the subjective effects of psychedelics, possibly because SSRIs cause downregulation of 5-HT2A receptors, making a person less sensitive to substances affecting these receptors.

MDMA + SSRI/SNRI:

MDMA is completely blocked by SSRIs and SNRIs, meaning that therapeutic or recreational effects will be significantly reduced rather than causing serotonin syndrome.

Ayahuasca + Antidepressants:

☠️ TOXIC: This combination carries the highest risk. Ayahuasca contains MAOIs (monoamine oxidase inhibitors) and can cause serotonin syndrome when combined with antidepressants. Anyone taking an antidepressant, especially an SSRI or tricyclic antidepressant (TCA), will be at potential risk of serotonin syndrome when consuming ayahuasca, because this would be equivalent to taking a monoamine oxidase inhibiting medication.

Lithium

#

☠️ TOXIC: Lithium and psychedelics may increase the risk of seizures.

MAOIs

#

MDMA + MAOIs:

The highest morbidity rates occurred from combining MDMA with MAOIs such as moclobemide or phenelzine, including significant hyperthermia, seizure-like activity, and altered mental status indicative of unrecognized serotonin syndrome symptoms, many of which resulted in fatalities.

Alcohol

#

Combining psychedelics with alcohol can:

• Intensify nausea and vomiting
• Increase risk of injury
• Impair ability to cope with challenging experiences
• Increase risk of dehydration

Amanita muscaria and GABA-Acting Drugs

#

⚠️ WARNING: Amanita muscaria is not compatible with GABA-acting medications, including benzodiazepines, opioids, and muscle relaxants, as combining these substances can significantly increase risks associated with respiratory depression and excessive sedation.

5. Psychological Risks

#

Bad Trips: Definition and Mechanisms

#

Definition:

A bad trip (also known as acute hallucinogen intoxication, psychedelic crisis, or emergence phenomenon) is an acute adverse psychological reaction to the effects of psychoactive substances, namely psychedelics.

Possible Adverse Reactions Include:

• Anxiety and panic
• Depersonalization
• Ego dissolution
• Paranoia
• Physiological symptoms: dizziness, palpitations

The Role of Set and Setting

#

Research shows that set (internal state) and setting (external environment) of substance use influence how people respond.

Set — the internal state, mindset, attitude, knowledge, and even nervous system state that a person brings to the journey. If you are stressed and rushed, this can affect the journey. If calm and relaxed, this improves the likelihood of an easier journey.

Setting — the physical and social environment in which the experience occurs.

HPPD (Hallucinogen Persisting Perception Disorder)

#

DSM-5 Definition:

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines HPPD as re-experiencing one or more perceptual symptoms originally experienced during hallucinogen intoxication.

DSM-V Criteria:

1. Re-experiencing one or more perceptual symptoms experienced during hallucinogen intoxication
2. Symptoms causing clinically significant distress or impairment in important areas of functioning
3. Symptoms that cannot be attributed to an underlying medical condition and are not explained by another mental disorder

Prevalence:

A web-based study estimated the overall prevalence of HPPD among psychedelic users at 4.2%, with 10.5% being female and the average age being 21.6 years.

Substances Associated with HPPD:

An extensive list of psychoactive substances has been identified and linked to HPPD development, including:

• Lysergamides: LSD, LSA
• Tryptamines: psilocybin, DMT
• Phenethylamines: 2C-B, MDMA, MDA, mescaline
• Dissociatives: ketamine, dextromethorphan
• Cannabis and synthetic cannabinoids

Risk Factors:

• Genetic predisposition: There are several reports where patients were diagnosed after single use, which strongly indicates possible genetic predisposition
• Drug interactions: Combining recreational or medical drugs acting on 5HT2-a receptors, such as SSRIs, sharply increases the chances of developing HPPD
• Psychological factors: There is preliminary evidence that those who develop distressing HPPD have higher trait anxiety or experienced increased baseline anxiety from a possibly negative psychedelic experience
• Comorbid conditions: A significant number reporting HPPD also describe comorbid depersonalization-derealization and anxiety disorders

Psychotic Episodes and Predisposition

#

Current Recommendations:

Current research considers schizophrenia a contraindication to psychedelic use along with personal or family history of schizophrenia, schizoaffective disorder, bipolar disorder type 1, suicidal ideation, and those experiencing psychotic episodes in the context of depression.

Bipolar Disorder and Mania Risk:

Psychedelic use increases the risk of mania with psychotic features in people with personal or family history of bipolar disorder. Since those with family history of bipolar disorder have higher risk of developing mania/hypomania, treatment-induced mania or hypomania is a hypothetical risk in the context of psilocybin therapy clinical trials.

Psychotic Disorders and Genetic Vulnerability:

Research indicates potential interaction between psychedelic use and genetic vulnerability in predicting adverse events such as prolonged psychosis. Additionally, prolonged psychosis may be incredibly dangerous for people who have personal or family history of primary psychotic or affective disorders such as schizophrenia, schizoaffective disorder, or bipolar disorder type 1.

Contradictory Data:

Notably, there is no clear evidence of high rates of psychedelic-induced psychosis in patients receiving antipsychotic treatment, and some researchers suggest that psychedelic use attenuates (or does not affect) psychosis risk in people with personal or family history of psychotic disorders.

Family History:

Psychotic symptoms were highest among respondents who reported lifetime psychedelic use and family history of psychotic or bipolar disorders, suggesting that genetic predisposition may be a significant risk factor.

6. Legal Status by Jurisdiction

#

Psilocybin

#

Portugal:

Portugal decriminalized all drugs for personal use in 2001, including psilocybin. Possession of small quantities is not a criminal offense and is instead handled through public health services. However, sale is illegal, but people are not prosecuted for possessing or using mushrooms in small quantities.

Netherlands:

In the Netherlands, psilocybin and magic mushrooms are illegal. However, magic truffles containing psilocybin can be legally sold and purchased. The legal distinction arose in the Netherlands, which banned mushrooms in 2008 but left truffles legal.

Brazil:

Brazil stands out as one of the few places where psilocybin is not included in any federal law, making its use and cultivation technically legal. In practice, spiritual and therapeutic use is widespread and not subject to legal intervention when done privately.

More specifically, ANVISA (the health agency) prohibits the molecules psilocybin and psilocin in its List F2, but the mushroom Psilocybe cubensis as a species is not explicitly listed. This technical detail allows websites to openly sell kits and fresh mushrooms.

Russia:

Information about the legal status of psilocybin in Russia in 2024-2025 sources is absent, suggesting continuation of strict prohibition.

USA (states with decriminalization/legalization):

• Oregon (2020): Measure 109 legalized therapeutic use of psilocybin
• Colorado (2022): Proposition 122 decriminalized psilocybin and created regulated access framework
• Cities: Denver, Oakland, Santa Cruz, Washington D.C., Detroit, Seattle, and others have decriminalized

European Union:

Most EU countries classify psilocybin as a Schedule I controlled substance.

Amanita muscaria and Muscimol

#

USA:

Amanita muscaria ingredients are not listed as controlled substances under the federal Controlled Substances Act (CSA) and are not approved by the FDA as dietary supplements or drugs.

Legal for cultivation and possession in most states, except:

• Louisiana: State Act No. 159 specifically names Amanita Muscaria as a mind-altering plant and makes possession or purchase illegal

Europe:

Legal everywhere in Europe except:

• Romania (complete ban)
• Netherlands (complete ban)
• Poland (sale prohibited)
• Lithuania (classified as controlled substance in 2025)

Germany, Italy, and the United Kingdom do not classify Amanita Muscaria as controlled substances.

Table: Legal Status by Jurisdiction (2025)

#

7. Harm Reduction: Minimizing Risks

#

⚠️ Substance Testing

#

DanceSafe and Reagent Test Kits:

DanceSafe is the original producer of drug checking kits in North America and the only non-profit manufacturer in the country, setting industry standards since 1999.

How Reagents Work:

Reagents are chemicals that acquire specific colors when in contact with certain drugs. However, reagents cannot detect every drug, cannot tell how pure or potent your drugs are, and even if you get expected color reactions for the desired drug, there may still be one or more other drug substances present.

For LSD and Psychedelics:

The Ehrlich reagent serves as an important first line of defense against accidentally taking misrepresented drugs and will turn purple in the presence of indoles, which includes LSD, psilocybin, DMT, and others.

Fentanyl Test Strips:

DanceSafe produces fentanyl test strips that use an antibody with high specificity for fentanyl and its analogues, making them one of the most accurate harm reduction tools, as fentanyl is a potent synthetic opioid that has caused a rise in overdoses across the United States.

Dosages and Gradual Titration

#

Start with Low Doses:

• Psilocybin: 0.5-1 g dried mushrooms for first experience
• Amanita muscaria: <1 g dried mushroom (⚠️ dosing extremely unreliable due to 10× variability in active substance content between samples — see https://lucerna.folkup.app/studies/mushroom-brain-amanita/; indicated dose is a guideline, not a safe recommendation)
• LSD: 50-75 μg

“Start Low, Go Slow” Rule:

• Wait for full effect (1-2 hours for most psychedelics) before increasing dose
• Don’t increase dose in one session (tolerance develops quickly)

Importance of Setting

#

Ideal Setting:

• Safe, familiar place
• Comfortable temperature and lighting
• No risk of unexpected intrusions
• Access to water and toilet
• Comfortable furniture/place to rest

Avoid:

• Unfamiliar places
• Large crowds (for first experience)
• Situations requiring responsibility/decision-making
• Driving or dangerous machinery

Trip Sitter: Role and Responsibility

#

Who is a Trip Sitter:

A sober, trusted person who stays with the psychedelic user to ensure physical and emotional safety.

Responsibilities:

• Creating a safe, supportive environment
• Minimal intervention when experience is proceeding positively
• Providing comfort and reorientation during anxiety
• Ensuring physical safety
• Readiness to seek medical help if necessary

7 Ways to Help Someone Having a Bad Trip (Zendo Project):

1. Sit with them — physical presence is calming
2. Remind them they are under the influence of a substance and the effect will pass
3. Create a calm environment (dim lights, quiet music)
4. Encourage deep breathing
5. Don’t leave them alone
6. Don’t dismiss the experience
7. Know when to seek medical help

What to Do During a Bad Trip

#

Self-Help Techniques:

1. Mindful breathing: diaphragmatic breathing calms the nervous system
2. Change of environment: moving to another room or outdoors
3. Music: calming, familiar music
4. Remind yourself: “This is temporary, I’m safe, this will pass”
5. Accept the experience: resistance intensifies distress

Pharmacological Intervention:

In most cases when anxiety arises during a controlled psychedelic experience, reassurance from the session monitor is sufficient for its resolution; however, if distress becomes intense, it can be treated pharmacologically, for example, with the benzodiazepine diazepam.

When to Call Emergency Services

#

☠️ CALL EMERGENCY SERVICES IMMEDIATELY FOR:

• Seizures
• Loss of consciousness
• Temperature >39°C or <36°C
• Severe hypertension or tachycardia
• Difficulty breathing
• Signs of heart attack or stroke
• Suicidal actions or intentions
• Aggressive behavior dangerous to self or others
• No improvement after 12+ hours

What to Tell Medics:

• What substance was taken (if known)
• Quantity and time of ingestion
• Weight and age of the victim
• Current symptoms
• Any medications being taken

8. Sources

#

[1] Medscape. Mushroom Toxicity: Background, Pathophysiology, Etiology.

[2] PMC. (2025). Mushroom poisoning: An updated review.

[3] Sage Journals. (2018). Epidemiology and clinics of mushroom poisoning in Northern Italy: A 21-year retrospective analysis.

[4] NCBI Bookshelf. Amatoxin Mushroom Toxicity - StatPearls.

[5] CDC MMWR. (2017). Amanita phalloides Mushroom Poisonings — Northern California, December 2016.

[6] NCBI Bookshelf. Mushroom Toxicity - StatPearls.

[7] PMC. (2013). Muscarinic Toxicity Among Family Members After Consumption of Mushrooms.

[8] OPSS. Mushrooms in dietary supplements.

[9] Psychopharmacology Institute. Examining the Combined Use of Psychedelics and Psychiatric Drugs.

[10] Sage Journals. (2025). Concomitant use of antidepressants and classic psychedelics: A scoping review.

[11] PMC. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

[12] Wikipedia. Bad trip.

[13] PMC. (2022). Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.

[14] Zendo Project. 7 Ways To Help Someone Who’s Having A Bad Trip.

[15] Wikipedia. Hallucinogen persisting perception disorder.

[16] Nature. (2024). Neuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD).

[17] PMC. (2018). Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.

[18] PMC. (2024). A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?

[19] UCSF Psychedelics. Medical Contraindications to “Classic” Psychedelic Use.

[20] PMC. (2024). Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.

[21] Wikipedia. Legal status of psilocybin mushrooms.

[22] The Buena Vida. (2025). Global Legal Status of Psilocybin: Updated Map (2025).

[23] Wikipedia. Legal status of psychoactive Amanita mushrooms.

[24] DanceSafe. Home.

[25] DanceSafe. LSD Testing Kit.

FolkUp Research Lab | Lucerna